Showing results (421-430 of 575) with videos related to

Sort By:
Pageof 58
Lab on a Chip|September 18, 2024
Integrated microfluidic multiple electrode aggregometry for point-of-care platelet function analysisX Zhao, V R Gopal, F Lozano-Juan, et al.
Acta Neurologica Scandinavica|February 10, 2011
Cognitive impairment using education-based cutoff points for CMMSE scores in elderly Chinese people of agricultural and rural Shanghai ChinaG-H Cui, Y-H Yao, R-F Xu, et al.
Molecular Cancer Therapeutics|May 27, 2010
Induction of clusterin by AKT--role in cytoprotection against docetaxel in prostate tumor cellsBin Zhong, David A Sallman, Danielle L Gilvary, et al.
The Journal of Biological Chemistry|March 24, 2005
ArgBP2gamma interacts with Akt and p21-activated kinase-1 and promotes cell survivalZeng-qiang Yuan, Donghwa Kim, Satoshi Kaneko, et al.
International Journal of Cancer|August 13, 2015
STAT3 polymorphisms may predict an unfavorable response to first-line platinum-based therapy for women with advanced serous epithelial ovarian cancerJennifer Permuth-Wey, William J Fulp, Brett M Reid, et al.
Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi|June 27, 2017
[Spectrum and case fatality of inpatients with malignant tumors from 1995 to 2014 in Shenzhen city]X B Wang, L C Hong, Y Z Wei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2003
Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancerTatiana M Gritsko, Domenico Coppola, June E Paciga, et al.
Cancer Research|August 17, 2001
Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3KM Sun, J E Paciga, R I Feldman, et al.
Cancer Letters|July 30, 2005
Regression of NMU-induced mammary tumors with the combination of melatonin and 9-cis-retinoic acidK Melancon, Q Cheng, T L Kiefer, et al.
ESMO Open|December 16, 2025
TQB2440 compared with reference pertuzumab for HER2-positive, ER/PgR-negative, early or locally advanced breast cancer: a multicenter, randomized, double-blind, parallel-controlled, phase III equivalence trialS Wang, N Li, Q Cheng, et al.
Pageof 58